PUBLIC COMPANY
saveSHANGHAI HENLIUS BIOTECH
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors
- phase1A Phase I Study of HLX109 in Healthy Participants
- phase1Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11
- phase1A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
- phase3A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- phase1A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
- phase1A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
🐶 Hiring Signal
News
- AstraZeneca scores in lung cancer; Sandoz inks a China dealA combination of AstraZeneca’s Tagrisso and Hutchmed’s Orpathys extended survival for some lung cancer patients. Elsewhere, MapLight floated the idea of partnering on its autism drug.biopharma_dive · 3mo ago
- Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilarsThe initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.biospace · 3mo ago
- STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and moreAstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacksstat · 3mo ago
comments(0)
5-min edit window · permanent after that